CDT
Conduit Pharmaceuticals Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.30M
P/E Ratio
—
EPS
$-1177.89
Beta
2.08
52W High
$1582.50
52W Low
$2.21
50-Day MA
$9.84
200-Day MA
$105.12
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing cutting-edge therapies for oncology and rare diseases, addressing significant unmet medical needs. Leveraging its proprietary drug delivery platform, Conduit enhances the efficacy and safety profiles of existing treatments, aiming to optimize patient outcomes while minimizing adverse effects. With a highly experienced management team and a focus on strategic partnerships, the company is strategically positioned to advance its innovative product pipeline and contribute meaningfully to the healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-24.74M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -345.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-77.82 |
| Price-to-Book | 5.16 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -55.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.86M |
| Float | $2.78M |
| % Insiders | 73.06% |
| % Institutions | 0.02% |
Data last updated: 5/1/2026